LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Karger, Matthias"
  2. AU="Shewade, Hemant Deepak"
  3. AU="Ninic, Sanja"
  4. AU="Nitta, Takashi"
  5. AU="Catanesi, M. G."
  6. AU="Kim, E. J."
  7. AU="De, Yanyan"
  8. AU="Zheng-Yan, Gao"
  9. AU="Carvajal-Maldonado, Denisse"
  10. AU="Gallagher, Julia E"
  11. AU="Skelin, Ivan"
  12. AU="Pinarli, Faruk Güçlü"
  13. AU=Carmina E
  14. AU=Abi-Rafeh Jad
  15. AU="Jalil, Yorschua F"
  16. AU="Barber, M"
  17. AU="Ritt, Luiz Eduardo Fonteles"
  18. AU="Qiu, Jiajing"
  19. AU=Wang Heping
  20. AU="Miyazaki, Masashi"
  21. AU="R Kulkarni"
  22. AU="Braga, D."
  23. AU="Mwenda, Mulenga"
  24. AU="Li, Baohua"
  25. AU="Zhang, Nasen Jonathan"
  26. AU="Scotlandi, Katia"
  27. AU="Thomson, M A"
  28. AU=New Sophie E P
  29. AU="Fenrich, Craig A"
  30. AU="Staehelin, Cornelia"
  31. AU="Akhtar, Suraiya"
  32. AU="Georgel, Philippe"
  33. AU="Gruenewald, Leon D"
  34. AU="Charron, Morgane"
  35. AU="Leona S. Alizadeh" AU="Leona S. Alizadeh"
  36. AU="Soriano, Stéphane"
  37. AU="Lin, Pao-Yen"
  38. AU="Mudali, Gayathri"
  39. AU="McElveen, John T"
  40. AU="Kraimps, Jean-Louis"
  41. AU="Patel, Sheila K"
  42. AU="Zian, Zeineb"
  43. AU="Langley, Jonathan"
  44. AU="Bell, Thomas G."
  45. AU="Harris, Charles"
  46. AU="Lai, Renfa"
  47. AU="Sakane, Tatsuya"
  48. AU="Mirza, I."
  49. AU="Beatriz Amorim Beltrão"
  50. AU="Wildman, D"
  51. AU="Manghi, Manoel"
  52. AU="van Dinther, Maarten"
  53. AU="Adams, Ashley L"
  54. AU="Zhang, Er-Bin"
  55. AU="Diuk-Wasser, Maria A"
  56. AU="Chowdhury, Muhtamim"
  57. AU="Rivas, Manuel A"
  58. AU="Mangelis, Anastasios"
  59. AU="Simpson, Tina Y"
  60. AU="Li, Peirang"
  61. AU="Zhang, Zhao-Liang"
  62. AU="Perner, Sven"
  63. AU=Suwanwongse Kulachanya AU=Suwanwongse Kulachanya
  64. AU="Rose, Jacqueline"
  65. AU="E Lostis"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Buch ; Dissertation / Habilitation: Laserdeposition und In-situ-RHEED-Untersuchungen von YBa2Cu3O7 als Grundlage für die Präparation von Mehrlagenbauelementen

    Karger, Matthias

    (Berichte aus dem Institut für Elektrische Messtechnik und Grundlagen der Elektrotechnik ; 30)

    2009  

    Verfasserangabe von Matthias Karger
    Serientitel Berichte aus dem Institut für Elektrische Messtechnik und Grundlagen der Elektrotechnik ; 30
    Schlagwörter RHEED ; Schichtwachstum ; Hochtemperatursupraleiter ; Epitaxieschicht ; Laserbeschichten
    Sprache Deutsch
    Umfang VIII, 112 S., Ill., graph. Darst.
    Verlag Mensch-und-Buch-Verl
    Erscheinungsort Berlin
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Techn. Univ., Diss.--Braunschweig, 2008
    ISBN 9783866645998 ; 3866645996
    Datenquelle Katalog der Technische Informationsbibliothek Hannover

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel: Using benzophenone-functionalized phosphonic acid to attach thin polymer films to titanium surfaces.

    Griep-Raming, Nina / Karger, Matthias / Menzel, Henning

    Langmuir : the ACS journal of surfaces and colloids

    2004  Band 20, Heft 26, Seite(n) 11811–11814

    Sprache Englisch
    Erscheinungsdatum 2004-12-21
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2005937-1
    ISSN 1520-5827 ; 0743-7463
    ISSN (online) 1520-5827
    ISSN 0743-7463
    DOI 10.1021/la0485327
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

    van den Berg, Joost H / Heemskerk, Bianca / van Rooij, Nienke / Gomez-Eerland, Raquel / Michels, Samira / van Zon, Maaike / de Boer, Renate / Bakker, Noor A M / Jorritsma-Smit, Annelies / van Buuren, Marit M / Kvistborg, Pia / Spits, Hergen / Schotte, Remko / Mallo, Henk / Karger, Matthias / van der Hage, Joris A / Wouters, Michel W J M / Pronk, Loes M / Geukes Foppen, Marnix H /
    Blank, Christian U / Beijnen, Jos H / Nuijen, Bastiaan / Schumacher, Ton N / Haanen, John B A G

    Journal for immunotherapy of cancer

    2020  Band 8, Heft 2

    Abstract: Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across ... ...

    Abstract Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.
    Purpose: Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.
    Experimental: Ten patients were treated with TIL therapy. Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed. Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.
    Results: Five out of 10 patients, who were all anti-PD-1 naïve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years. Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed. For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.
    Conclusion: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.
    Mesh-Begriff(e) Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Lymphocytes, Tumor-Infiltrating/metabolism ; Male ; Melanoma/genetics ; Melanoma/pathology ; Middle Aged ; T-Lymphocytes/metabolism
    Sprache Englisch
    Erscheinungsdatum 2020-08-04
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-000848
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

    Rohaan, Maartje W / Borch, Troels H / van den Berg, Joost H / Met, Özcan / Kessels, Rob / Geukes Foppen, Marnix H / Stoltenborg Granhøj, Joachim / Nuijen, Bastiaan / Nijenhuis, Cynthia / Jedema, Inge / van Zon, Maaike / Scheij, Saskia / Beijnen, Jos H / Hansen, Marten / Voermans, Carlijn / Noringriis, Inge M / Monberg, Tine J / Holmstroem, Rikke B / Wever, Lidwina D V /
    van Dijk, Marloes / Grijpink-Ongering, Lindsay G / Valkenet, Ludy H M / Torres Acosta, Alejandro / Karger, Matthias / Borgers, Jessica S W / Ten Ham, Renske M T / Retèl, Valesca P / van Harten, Wim H / Lalezari, Ferry / van Tinteren, Harm / van der Veldt, Astrid A M / Hospers, Geke A P / Stevense-den Boer, Marion A M / Suijkerbuijk, Karijn P M / Aarts, Maureen J B / Piersma, Djura / van den Eertwegh, Alfons J M / de Groot, Jan-Willem B / Vreugdenhil, Gerard / Kapiteijn, Ellen / Boers-Sonderen, Marye J / Fiets, W Edward / van den Berkmortel, Franchette W P J / Ellebaek, Eva / Hölmich, Lisbet R / van Akkooi, Alexander C J / van Houdt, Winan J / Wouters, Michel W J M / van Thienen, Johannes V / Blank, Christian U / Meerveld-Eggink, Aafke / Klobuch, Sebastian / Wilgenhof, Sofie / Schumacher, Ton N / Donia, Marco / Svane, Inge Marie / Haanen, John B A G

    The New England journal of medicine

    2022  Band 387, Heft 23, Seite(n) 2113–2125

    Abstract: Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with ...

    Abstract Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma.
    Methods: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×10
    Results: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression.
    Conclusions: In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).
    Mesh-Begriff(e) Humans ; Cell- and Tissue-Based Therapy ; Ipilimumab/adverse effects ; Lymphocytes, Tumor-Infiltrating ; Melanoma/drug therapy ; Immunotherapy, Adoptive
    Chemische Substanzen Ipilimumab
    Sprache Englisch
    Erscheinungsdatum 2022-12-07
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2210233
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.34: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang